226 related articles for article (PubMed ID: 21796420)
1. [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part B: Skin].
Ehmann LM; Heinemann V; Wollenberg A
Internist (Berl); 2011 Nov; 52(11):1359-64. PubMed ID: 21796420
[TBL] [Abstract][Full Text] [Related]
2. [Therapy with epidermal growth factor receptor inhibitors. Clinical spectrum of cutaneous adverse effects].
Gerber PA; Buhren BA; Kürle S; Homey B
Hautarzt; 2010 Aug; 61(8):654-61. PubMed ID: 20628713
[TBL] [Abstract][Full Text] [Related]
3. Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails.
Lacouture M; Sibaud V
Am J Clin Dermatol; 2018 Nov; 19(Suppl 1):31-39. PubMed ID: 30374901
[TBL] [Abstract][Full Text] [Related]
4. Semiology of skin toxicity associated with epidermal growth factor receptor (EGFR) inhibitors.
Peuvrel L; Bachmeyer C; Reguiai Z; Bachet JB; André T; Bensadoun RJ; Bouché O; Ychou M; Dréno B
Support Care Cancer; 2012 May; 20(5):909-21. PubMed ID: 22361824
[TBL] [Abstract][Full Text] [Related]
5. [New tyrosine kinase and EGFR inhibitors in cancer therapy. Cardiac and skin toxicity as relevant side effects. Part A: heart].
Rottlaender D; Reda S; Motloch LJ; Hoppe UC
Internist (Berl); 2011 Oct; 52(10):1245-55. PubMed ID: 21792599
[TBL] [Abstract][Full Text] [Related]
6. Dermatological side effects of targeted antineoplastic therapies: a prospective study.
Agirgol S; Çaytemel C; Pilanci KN
Cutan Ocul Toxicol; 2020 Dec; 39(4):380-384. PubMed ID: 33028137
[TBL] [Abstract][Full Text] [Related]
7. Adverse Reaction to Cetuximab, an Epidermal Growth Factor Receptor Inhibitor.
Štulhofer Buzina D; Martinac I; Ledić Drvar D; Čeović R; Bilić I; Marinović B
Acta Dermatovenerol Croat; 2016 Apr; 24(1):70-2. PubMed ID: 27149134
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous adverse effects of targeted therapies: Part I: Inhibitors of the cellular membrane.
Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
J Am Acad Dermatol; 2015 Feb; 72(2):203-18; quiz 219-20. PubMed ID: 25592338
[TBL] [Abstract][Full Text] [Related]
9. Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer.
Ocvirk J; Cencelj S
J Eur Acad Dermatol Venereol; 2010 Apr; 24(4):453-9. PubMed ID: 19793151
[TBL] [Abstract][Full Text] [Related]
10. Skin Manifestations of Targeted Antineoplastic Therapy.
Sanmartín O
Curr Probl Dermatol; 2018; 53():93-104. PubMed ID: 29131041
[TBL] [Abstract][Full Text] [Related]
11. Cutaneous drug eruptions associated with the use of new oncological drugs.
Belloni B; Schönewolf N; Rozati S; Goldinger SM; Dummer R
Chem Immunol Allergy; 2012; 97():191-202. PubMed ID: 22613863
[TBL] [Abstract][Full Text] [Related]
12. Skin problems and EGFR-tyrosine kinase inhibitor.
Kozuki T
Jpn J Clin Oncol; 2016 Apr; 46(4):291-8. PubMed ID: 26826719
[TBL] [Abstract][Full Text] [Related]
13. Dermatologic Reactions to Targeted Therapy: A Focus on Epidermal Growth Factor Receptor Inhibitors and Nursing Care.
Barton-Burke M; Ciccolini K; Mekas M; Burke S
Nurs Clin North Am; 2017 Mar; 52(1):83-113. PubMed ID: 28189168
[TBL] [Abstract][Full Text] [Related]
14. Targeted tumour therapy induced papulopustular rash and other dermatologic side effects: a retrospective study.
Yalici-Armagan B; Ayanoglu BT; Demirdag HG
Cutan Ocul Toxicol; 2019 Sep; 38(3):261-266. PubMed ID: 31010330
[No Abstract] [Full Text] [Related]
15. Management of cutaneous adverse events induced by anti-EGFR (epidermal growth factor receptor): a French interdisciplinary therapeutic algorithm.
Reguiai Z; Bachet JB; Bachmeyer C; Peuvrel L; Beylot-Barry M; Bezier M; Boucher E; Chevelle C; Colin P; Guimbaud R; Mineur L; Richard MA; Artru P; Dufour P; Gornet JM; Samalin E; Bensadoun RJ; Ychou M; André T; Dreno B; Bouché O
Support Care Cancer; 2012 Jul; 20(7):1395-404. PubMed ID: 22539049
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy and skin reactions.
Fabbrocini G; Cameli N; Romano MC; Mariano M; Panariello L; Bianca D; Monfrecola G
J Exp Clin Cancer Res; 2012 May; 31(1):50. PubMed ID: 22640460
[TBL] [Abstract][Full Text] [Related]
17. NSAIDs may prevent EGFR-TKI-related skin rash in non-small cell lung cancer patients
.
Iimura Y; Shimomura H; Yasu T; Imanaka K; Ogawa R; Ito A; Suzuki K; Yamaguchi G; Kawasaki N; Konaka C
Int J Clin Pharmacol Ther; 2018 Nov; 56(11):551-554. PubMed ID: 30232957
[TBL] [Abstract][Full Text] [Related]
18. Erlotinib-related skin toxicities: treatment strategies in patients with metastatic non-small cell lung cancer.
Kiyohara Y; Yamazaki N; Kishi A
J Am Acad Dermatol; 2013 Sep; 69(3):463-72. PubMed ID: 23602600
[TBL] [Abstract][Full Text] [Related]
19. [Cutaneous side effects of EGFR inhibitors--appearance and management].
Wollenberg A; Kroth J; Hauschild A; Dirschka T
Dtsch Med Wochenschr; 2010 Jan; 135(4):149-54. PubMed ID: 20101558
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy.
Reyes-Habito CM; Roh EK
J Am Acad Dermatol; 2014 Aug; 71(2):217.e1-217.e11; quiz 227-8. PubMed ID: 25037801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
